Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CING
vs
S&P 500
CING
S&P 500
Over the past 12 months, CING has outperformed S&P 500, delivering a return of +14% compared to S&P 500's +14% growth.
Stocks Performance
CING vs S&P 500
Performance Gap
CING vs S&P 500
Performance By Year
CING vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cingulate Inc
Glance View
Cingulate is a clinical-stage pharmaceutical company that develops prescription medicines using its own timed-release drug delivery technology. Its main work is creating oral drugs that release medicine in a controlled pattern over the day, with a focus on attention deficit hyperactivity disorder and other central nervous system conditions. The company is still in development, so it is not a broad drug seller; its value comes from moving candidate medicines through testing and approval. Its lead programs are built around a platform designed to give patients a smoother, longer-lasting effect from a single daily dose. In simple terms, Cingulate sells the idea of better dosing and more predictable medicine timing, not a large catalog of approved drugs. The main customers it ultimately seeks are patients, doctors, and, through partnerships, larger pharmaceutical companies that may help commercialize its products. Cingulate makes money mainly by advancing its drug candidates, securing development or licensing partnerships, and eventually earning product sales or royalty income if any candidate reaches the market. What makes the business different is that it sits at the intersection of drug development and delivery technology: it is trying to improve how an existing medicine works by changing when it is released in the body, rather than inventing an entirely new chemical from scratch.